期刊
JOURNAL OF TRANSLATIONAL MEDICINE
卷 12, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1479-5876-12-107
关键词
Glioblastoma; Astrocytoma; Glioma; Immunotherapy; Preclinical; Animal models; Murine; Immune response; Immunosuppression
资金
- National Research Education Foundation through the American Association of Neurological Surgeons
- Doris Duke Charitable Foundation
- Reza and Georgianna Khatib Endowed Chair in Skull Base Tumor Surgery at UCSF
- Northwestern University
Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352: 987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据